<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Effects of Ranibizumab on Exudative Disciform Scars

Name: Effects of Ranibizumab on Exudative Disciform Scars
Keywords: Aged, 80 and over, Male, Vascular Endothelial Growth Factor A, Visual Acuity, Antibodies, Monoclonal, Angiogenesis Inhibitors, Exudates and Transudates, Middle Aged, Antibodies, Monoclonal, Humanized, Choroidal Neovascularization

descriptionPublicationkeyboard_double_arrow_right Article 01 Jul 2009 English Publisher:SLACK, Inc.Journal:Ophthalmic Surgery, Lasers and Imaging Retina, volume 40, pages 366-372 (issn: 2325-8160, eissn: 2325-8179,

Authors: Jeffrey S. Heier; Albert R. Frederick; Trexler M. Topping; Eleanor F Morley; Michael Morley; Anna Berry; Mark Hughes; +5 Authors

doi: 10.3928/15428877-20096030-03

pmid: 19634740

Effects of Ranibizumab on Exudative Disciform Scars

- Summary
- Subjects
- Metrics

Abstract

Background and Objective: To evaluate the effect of intravitreal ranibizumab in patients with leaking disciform scars. Patients and Methods: In this retrospective case series, 31 eyes received one or two ranibizumab injections for treatment of choroidal neovascularization. Visual acuity, central retinal thickness, and macular volume were measured prior to injection and at 1-month follow-up. Results: After one injection (n = 31), mean optical coherence tomography (OCT) central foveal thickness decreased from 317 to 242 µm ( P = .00016). Mean OCT macular volume decreased from 7.89 to 6.80 mm 3 ( P = .00019). After two injections (n = 12), mean OCT central foveal thickness decreased from 310 to 248 µm following the second injection ( P = .04). Mean OCT macular volume decreased from 7.80 to 6.43 mm 3 at 1-month follow-up after a second injection ( P = .006). There was no significant change in visual acuity after injections. Conclusion: In the short-term, ranibizumab decreases the leakage associated with choroidal neovascularization in chronic macular degeneration. [Ophthalmic Surg Lasers Imaging 2009;40:366–372.]

Related Organizations

Harvard University
United States

Keywords

Aged, 80 and over, Male, Vascular Endothelial Growth Factor A, Visual Acuity, Antibodies, Monoclonal, Angiogenesis Inhibitors, Exudates and Transudates, Middle Aged, Antibodies, Monoclonal, Humanized, Choroidal Neovascularization, Injections, Macular Degeneration, Treatment Outcome, Ranibizumab, Humans, Female, Tomography, Optical Coherence, Aged, Follow-Up Studies, Retrospective Studies

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average